EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO ‐1, PSO ‐2 and long‐term extension trials

April W Armstrong iD, Mark Lebwohl, Richard B Warren iD, Howard Sofen iD, Akimichi Morita iD, Carle Paul iD, Kim A Papp iD, Matthew J Colombo iD, Julie Scotto iD, John Vaile, Joe Zhuo, Eleni Vritzali und 5 weitere

Journal of the European Academy of Dermatology and Venereology · 2025-07 · 39 (7) · 1336-1351

DOI: 10.1111/jdv.20553 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 06.03.2025. Verfasst von April W Armstrong und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of California Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Psoriasis, Protein Kinase Inhibitors, Quinazolinones. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Objectives

To evaluate the safety and efficacy of deucravacitinib through 4 years in the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension (LTE) trials in psoriasis.

Methods

PSO‐1 and PSO‐2 (parent trials) randomized patients 1:2:1 to oral placebo, deucravacitinib 6 mg once daily (QD) or apremilast 30 mg twice daily. At 52 weeks, patients enrolled in the LTE trial received open‐label deucravacitinib 6 mg QD. Safety was evaluated in patients who received ≥1 dose of deucravacitinib at any time. Clinical and patient‐reported outcomes (PASI, PGA and DLQI) were analysed in patients who received continuous deucravacitinib from Day 1 of the parent trials and enrolled in the LTE trial.

Results

In total, 1519 patients received ≥1 dose of deucravacitinib, with cumulative exposure of 4392.8 person‐years (PY) through the data cut‐off of 1 November 2023. Exposure‐adjusted incidence rates (EAIRs)/100 PY of noted safety measures were comparable or decreased from the 1‐year to 4‐year cumulative period, respectively, for adverse events (AEs) (229.23, 131.68), serious AEs (including COVID‐19) (5.68, 5.01), deaths (0.20, 0.25), discontinuation due to AEs (4.38, 2.20), herpes zoster (0.81, 0.55), malignancies (1.02, 0.89), major adverse cardiovascular events (0.30, 0.32) and venous thromboembolism (0.20, 0.07). In patients who received continuous deucravacitinib ( n = 513), clinical and patient‐reported outcome rates were well maintained from 1 year through 4 years (e.g. PASI 90, 1 year, 45.6% [95% CI, 41.3%–50.0%], 4 years, 47.5% [42.6%–52.4%]; DLQI 0/1, 1 year, 51.5% [47.1%–55.9%], 4 years, 49.4% [44.4%–54.4%]).

Conclusions

Deucravacitinib demonstrated a consistent safety profile and durable efficacy through 4 years of treatment in patients with moderate to severe plaque psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisProtein Kinase InhibitorsQuinazolinonesHumansMaleFemaleMiddle AgedAdultTreatment OutcomeDouble-Blind Method

Substanzen

Protein Kinase InhibitorsQuinazolinones

Autor:innen und Institutionen

  • University of California Los Angeles, Los Angeles, California, USA.
  • Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.
  • NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Dermatology Research Associates, Los Angeles, California, USA.
  • Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

ORCID-Profile: April W Armstrong, Richard B Warren, Howard Sofen, Akimichi Morita, Carle Paul, Kim A Papp, Matthew J Colombo, Julie Scotto, Subhashis Banerjee, Diamant Thaçi, Bruce Strober

Zitieren

APA

Armstrong, A. W., Lebwohl, M., Warren, R. B., Sofen, H., Morita, A., Paul, C., Papp, K. A., Colombo, M. J., Scotto, J., Vaile, J., Zhuo, J., Vritzali, E., Berger, V., Schroeder, G., Banerjee, S., Thaçi, D., & Strober, B. (2025). Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO ‐1, PSO ‐2 and long‐term extension trials. Journal of the European Academy of Dermatology and Venereology, 39(7), 1336-1351. https://doi.org/10.1111/jdv.20553

Vancouver

Armstrong AW, Lebwohl M, Warren RB, Sofen H, Morita A, Paul C, et al. Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO ‐1, PSO ‐2 and long‐term extension trials. Journal of the European Academy of Dermatology and Venereology. 2025;39(7):1336-1351. doi:10.1111/jdv.20553

BibTeX
@article{Armstrong2025,
  author = {Armstrong, April W and Lebwohl, Mark and Warren, Richard B and Sofen, Howard and Morita, Akimichi and Paul, Carle and Papp, Kim A and Colombo, Matthew J and Scotto, Julie and Vaile, John and Zhuo, Joe and Vritzali, Eleni and Berger, Victoria and Schroeder, Georgene and Banerjee, Subhashis and Thaçi, Diamant and Strober, Bruce},
  title = {Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO ‐1, PSO ‐2 and long‐term extension trials},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  volume = {39},
  number = {7},
  pages = {1336--1351},
  doi = {10.1111/jdv.20553}
}
Kostenlos starten →